Retrospective Study on the Effects of Glucose Abnormality on COVID-19 Outcomes in Japan
Introduction To investigate the effects of glucose abnormality on outcomes of hospitalized coronavirus disease 2019 (COVID-19) patients in Japan. Methods This study retrospectively analyzed 393 COVID-19 patients admitted at Juntendo University Hospital. Patients were divided into subgroups according...
Gespeichert in:
| Veröffentlicht in: | Diabetes therapy 2022-02, Vol.13 (2), p.325-339 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 339 |
|---|---|
| container_issue | 2 |
| container_start_page | 325 |
| container_title | Diabetes therapy |
| container_volume | 13 |
| creator | Nishida, Yuya Mita, Tomoya Hiki, Makoto Matsushita, Yasushi Naito, Toshio Watada, Hirotaka |
| description | Introduction
To investigate the effects of glucose abnormality on outcomes of hospitalized coronavirus disease 2019 (COVID-19) patients in Japan.
Methods
This study retrospectively analyzed 393 COVID-19 patients admitted at Juntendo University Hospital. Patients were divided into subgroups according to history of diabetes and blood glucose (BG) levels and subsequently compared in terms of in-hospital death, invasive ventilation, or a composite of both.
Results
Patients with glucose abnormality demonstrated more risk factors for serious COVID-19, such as high body mass index, dyslipidemia, and hypertension, and higher biomarkers for inflammation compared to those with normal BG levels. Oxygen inhalation and steroid use were more frequent among patients with than without glucose abnormality. Invasive ventilation was more frequent in patients with diabetes (9.5% vs. 3.2%,
p
= 0.033) and BG ≥ 140 mg/dl (11.0% vs. 3.1%,
p
= 0.009) compared with those without diabetes and BG |
| doi_str_mv | 10.1007/s13300-022-01206-2 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8801191</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A694939360</galeid><sourcerecordid>A694939360</sourcerecordid><originalsourceid>FETCH-LOGICAL-c558t-ed0cd1bf03639f4af0ca0a9ac1d4245757e11b39c2a876056e1a7aa11cbdf2e13</originalsourceid><addsrcrecordid>eNp9kk1r3DAQhk1paUKaP9BDEfTSi5MZyV-6FJZtmiYEFvp5FLI82ijY0tayA_n31WbTTVNKpYPEzPO-YjSTZa8RThCgPo0oBEAOnOeAHKqcP8sOsalkXskKn-_vpTjIjmO8gbSElBLxZXYgSpBN0dSH2Y_PNI0hbshM7pbYl2nu7ljwbLomdmZtCkcWLDvvZxMisUXrwzjo3k331HL1_eJDjpKt5smEgSJznl3qjfavshdW95GOH86j7NvHs6_LT_nV6vxiubjKTVk2U04dmA5bC6IS0hbagtGgpTbYFbwo67ImxFZIw3VTV1BWhLrWGtG0neWE4ih7v_PdzO1AnSE_jbpXm9ENerxTQTv1NOPdtVqHW9U0gCi3Bu8eDMbwc6Y4qcFFQ32vPYU5Kl7xggMUok7o27_QmzCPPpWnuBQNFoC1fKTWuiflvA3pXbM1VYtKFlJIUUGiTv5Bpd3R4EzwZF2KPxHwncCkdsWR7L5GBLWdCLWbCJUmQt1PhOJJ9ObP39lLfvc_AWIHxJTyaxofS_qP7S-Flb75</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2938140179</pqid></control><display><type>article</type><title>Retrospective Study on the Effects of Glucose Abnormality on COVID-19 Outcomes in Japan</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Springer Nature OA Free Journals</source><creator>Nishida, Yuya ; Mita, Tomoya ; Hiki, Makoto ; Matsushita, Yasushi ; Naito, Toshio ; Watada, Hirotaka</creator><creatorcontrib>Nishida, Yuya ; Mita, Tomoya ; Hiki, Makoto ; Matsushita, Yasushi ; Naito, Toshio ; Watada, Hirotaka</creatorcontrib><description>Introduction
To investigate the effects of glucose abnormality on outcomes of hospitalized coronavirus disease 2019 (COVID-19) patients in Japan.
Methods
This study retrospectively analyzed 393 COVID-19 patients admitted at Juntendo University Hospital. Patients were divided into subgroups according to history of diabetes and blood glucose (BG) levels and subsequently compared in terms of in-hospital death, invasive ventilation, or a composite of both.
Results
Patients with glucose abnormality demonstrated more risk factors for serious COVID-19, such as high body mass index, dyslipidemia, and hypertension, and higher biomarkers for inflammation compared to those with normal BG levels. Oxygen inhalation and steroid use were more frequent among patients with than without glucose abnormality. Invasive ventilation was more frequent in patients with diabetes (9.5% vs. 3.2%,
p
= 0.033) and BG ≥ 140 mg/dl (11.0% vs. 3.1%,
p
= 0.009) compared with those without diabetes and BG < 140 mg/dl, respectively. Logistic regression analysis showed that BG ≥ 140 mg/dl was a risk factor for invasive ventilation [odds ratio (OR) 2.87, 95% CI 1.04–7.68,
p
= 0.037] or the composite outcome (OR 3.03, 95% CI 1.21–7.38,
p
= 0.015) even after adjusting for by age and gender. Kaplan-Meier analysis showed that glucose abnormality was significantly associated with invasive ventilation and that BG ≥ 140 mg/dl was a risk factor for invasive ventilation [hazard ratio (HR) 2.68, 95% CI 1.05–6.82,
p
= 0.039] and the composite of death and invasive ventilation (HR 2.77, 95% CI 1.21–6.37,
p
= 0.016) regardless of age and gender.
Conclusions
Glucose abnormality, particularly BG ≥ 140 mg/dl, was associated with serious outcomes among Japanese COVID-19 patients, suggesting the need to consider high BG as a major risk factor for poor clinical course also in Japan.</description><identifier>ISSN: 1869-6953</identifier><identifier>EISSN: 1869-6961</identifier><identifier>DOI: 10.1007/s13300-022-01206-2</identifier><identifier>PMID: 35098487</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Cardiology ; Coronaviruses ; COVID-19 ; Diabetes ; Diabetics ; Endocrinology ; Glucose ; Hospital patients ; Hyperglycemia ; Internal Medicine ; Medicine ; Medicine & Public Health ; Original Research ; Patient outcomes ; Risk factors ; Statistics ; Ventilation</subject><ispartof>Diabetes therapy, 2022-02, Vol.13 (2), p.325-339</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>COPYRIGHT 2022 Springer</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c558t-ed0cd1bf03639f4af0ca0a9ac1d4245757e11b39c2a876056e1a7aa11cbdf2e13</cites><orcidid>0000-0002-8396-423X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801191/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801191/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35098487$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nishida, Yuya</creatorcontrib><creatorcontrib>Mita, Tomoya</creatorcontrib><creatorcontrib>Hiki, Makoto</creatorcontrib><creatorcontrib>Matsushita, Yasushi</creatorcontrib><creatorcontrib>Naito, Toshio</creatorcontrib><creatorcontrib>Watada, Hirotaka</creatorcontrib><title>Retrospective Study on the Effects of Glucose Abnormality on COVID-19 Outcomes in Japan</title><title>Diabetes therapy</title><addtitle>Diabetes Ther</addtitle><addtitle>Diabetes Ther</addtitle><description>Introduction
To investigate the effects of glucose abnormality on outcomes of hospitalized coronavirus disease 2019 (COVID-19) patients in Japan.
Methods
This study retrospectively analyzed 393 COVID-19 patients admitted at Juntendo University Hospital. Patients were divided into subgroups according to history of diabetes and blood glucose (BG) levels and subsequently compared in terms of in-hospital death, invasive ventilation, or a composite of both.
Results
Patients with glucose abnormality demonstrated more risk factors for serious COVID-19, such as high body mass index, dyslipidemia, and hypertension, and higher biomarkers for inflammation compared to those with normal BG levels. Oxygen inhalation and steroid use were more frequent among patients with than without glucose abnormality. Invasive ventilation was more frequent in patients with diabetes (9.5% vs. 3.2%,
p
= 0.033) and BG ≥ 140 mg/dl (11.0% vs. 3.1%,
p
= 0.009) compared with those without diabetes and BG < 140 mg/dl, respectively. Logistic regression analysis showed that BG ≥ 140 mg/dl was a risk factor for invasive ventilation [odds ratio (OR) 2.87, 95% CI 1.04–7.68,
p
= 0.037] or the composite outcome (OR 3.03, 95% CI 1.21–7.38,
p
= 0.015) even after adjusting for by age and gender. Kaplan-Meier analysis showed that glucose abnormality was significantly associated with invasive ventilation and that BG ≥ 140 mg/dl was a risk factor for invasive ventilation [hazard ratio (HR) 2.68, 95% CI 1.05–6.82,
p
= 0.039] and the composite of death and invasive ventilation (HR 2.77, 95% CI 1.21–6.37,
p
= 0.016) regardless of age and gender.
Conclusions
Glucose abnormality, particularly BG ≥ 140 mg/dl, was associated with serious outcomes among Japanese COVID-19 patients, suggesting the need to consider high BG as a major risk factor for poor clinical course also in Japan.</description><subject>Cardiology</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Diabetes</subject><subject>Diabetics</subject><subject>Endocrinology</subject><subject>Glucose</subject><subject>Hospital patients</subject><subject>Hyperglycemia</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Research</subject><subject>Patient outcomes</subject><subject>Risk factors</subject><subject>Statistics</subject><subject>Ventilation</subject><issn>1869-6953</issn><issn>1869-6961</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kk1r3DAQhk1paUKaP9BDEfTSi5MZyV-6FJZtmiYEFvp5FLI82ijY0tayA_n31WbTTVNKpYPEzPO-YjSTZa8RThCgPo0oBEAOnOeAHKqcP8sOsalkXskKn-_vpTjIjmO8gbSElBLxZXYgSpBN0dSH2Y_PNI0hbshM7pbYl2nu7ljwbLomdmZtCkcWLDvvZxMisUXrwzjo3k331HL1_eJDjpKt5smEgSJznl3qjfavshdW95GOH86j7NvHs6_LT_nV6vxiubjKTVk2U04dmA5bC6IS0hbagtGgpTbYFbwo67ImxFZIw3VTV1BWhLrWGtG0neWE4ih7v_PdzO1AnSE_jbpXm9ENerxTQTv1NOPdtVqHW9U0gCi3Bu8eDMbwc6Y4qcFFQ32vPYU5Kl7xggMUok7o27_QmzCPPpWnuBQNFoC1fKTWuiflvA3pXbM1VYtKFlJIUUGiTv5Bpd3R4EzwZF2KPxHwncCkdsWR7L5GBLWdCLWbCJUmQt1PhOJJ9ObP39lLfvc_AWIHxJTyaxofS_qP7S-Flb75</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Nishida, Yuya</creator><creator>Mita, Tomoya</creator><creator>Hiki, Makoto</creator><creator>Matsushita, Yasushi</creator><creator>Naito, Toshio</creator><creator>Watada, Hirotaka</creator><general>Springer Healthcare</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8396-423X</orcidid></search><sort><creationdate>20220201</creationdate><title>Retrospective Study on the Effects of Glucose Abnormality on COVID-19 Outcomes in Japan</title><author>Nishida, Yuya ; Mita, Tomoya ; Hiki, Makoto ; Matsushita, Yasushi ; Naito, Toshio ; Watada, Hirotaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c558t-ed0cd1bf03639f4af0ca0a9ac1d4245757e11b39c2a876056e1a7aa11cbdf2e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cardiology</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Diabetes</topic><topic>Diabetics</topic><topic>Endocrinology</topic><topic>Glucose</topic><topic>Hospital patients</topic><topic>Hyperglycemia</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Research</topic><topic>Patient outcomes</topic><topic>Risk factors</topic><topic>Statistics</topic><topic>Ventilation</topic><toplevel>online_resources</toplevel><creatorcontrib>Nishida, Yuya</creatorcontrib><creatorcontrib>Mita, Tomoya</creatorcontrib><creatorcontrib>Hiki, Makoto</creatorcontrib><creatorcontrib>Matsushita, Yasushi</creatorcontrib><creatorcontrib>Naito, Toshio</creatorcontrib><creatorcontrib>Watada, Hirotaka</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nishida, Yuya</au><au>Mita, Tomoya</au><au>Hiki, Makoto</au><au>Matsushita, Yasushi</au><au>Naito, Toshio</au><au>Watada, Hirotaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retrospective Study on the Effects of Glucose Abnormality on COVID-19 Outcomes in Japan</atitle><jtitle>Diabetes therapy</jtitle><stitle>Diabetes Ther</stitle><addtitle>Diabetes Ther</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>13</volume><issue>2</issue><spage>325</spage><epage>339</epage><pages>325-339</pages><issn>1869-6953</issn><eissn>1869-6961</eissn><abstract>Introduction
To investigate the effects of glucose abnormality on outcomes of hospitalized coronavirus disease 2019 (COVID-19) patients in Japan.
Methods
This study retrospectively analyzed 393 COVID-19 patients admitted at Juntendo University Hospital. Patients were divided into subgroups according to history of diabetes and blood glucose (BG) levels and subsequently compared in terms of in-hospital death, invasive ventilation, or a composite of both.
Results
Patients with glucose abnormality demonstrated more risk factors for serious COVID-19, such as high body mass index, dyslipidemia, and hypertension, and higher biomarkers for inflammation compared to those with normal BG levels. Oxygen inhalation and steroid use were more frequent among patients with than without glucose abnormality. Invasive ventilation was more frequent in patients with diabetes (9.5% vs. 3.2%,
p
= 0.033) and BG ≥ 140 mg/dl (11.0% vs. 3.1%,
p
= 0.009) compared with those without diabetes and BG < 140 mg/dl, respectively. Logistic regression analysis showed that BG ≥ 140 mg/dl was a risk factor for invasive ventilation [odds ratio (OR) 2.87, 95% CI 1.04–7.68,
p
= 0.037] or the composite outcome (OR 3.03, 95% CI 1.21–7.38,
p
= 0.015) even after adjusting for by age and gender. Kaplan-Meier analysis showed that glucose abnormality was significantly associated with invasive ventilation and that BG ≥ 140 mg/dl was a risk factor for invasive ventilation [hazard ratio (HR) 2.68, 95% CI 1.05–6.82,
p
= 0.039] and the composite of death and invasive ventilation (HR 2.77, 95% CI 1.21–6.37,
p
= 0.016) regardless of age and gender.
Conclusions
Glucose abnormality, particularly BG ≥ 140 mg/dl, was associated with serious outcomes among Japanese COVID-19 patients, suggesting the need to consider high BG as a major risk factor for poor clinical course also in Japan.</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>35098487</pmid><doi>10.1007/s13300-022-01206-2</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-8396-423X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1869-6953 |
| ispartof | Diabetes therapy, 2022-02, Vol.13 (2), p.325-339 |
| issn | 1869-6953 1869-6961 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8801191 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Springer Nature OA Free Journals |
| subjects | Cardiology Coronaviruses COVID-19 Diabetes Diabetics Endocrinology Glucose Hospital patients Hyperglycemia Internal Medicine Medicine Medicine & Public Health Original Research Patient outcomes Risk factors Statistics Ventilation |
| title | Retrospective Study on the Effects of Glucose Abnormality on COVID-19 Outcomes in Japan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T15%3A09%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retrospective%20Study%20on%20the%20Effects%20of%20Glucose%20Abnormality%20on%20COVID-19%20Outcomes%20in%20Japan&rft.jtitle=Diabetes%20therapy&rft.au=Nishida,%20Yuya&rft.date=2022-02-01&rft.volume=13&rft.issue=2&rft.spage=325&rft.epage=339&rft.pages=325-339&rft.issn=1869-6953&rft.eissn=1869-6961&rft_id=info:doi/10.1007/s13300-022-01206-2&rft_dat=%3Cgale_pubme%3EA694939360%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2938140179&rft_id=info:pmid/35098487&rft_galeid=A694939360&rfr_iscdi=true |